Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274343 | 0.87 | ADORA1 (0.58) | ADORA1ADORA2AEGFRABL1ABL2 | |
| SCHEMBL4251031 | 0.81 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BIRAK1 | |
| SCHEMBL4251032 | 0.81 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BIRAK1 | |
| SCHEMBL4251034 | 0.81 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BIRAK1 | |
| SCHEMBL4260180 | 0.79 | ADORA1 (0.75) | ADORA1ADORA2AADORA3ADORA2BIRAK1 | |
| SCHEMBL4260177 | 0.79 | ADORA1 (0.75) | ADORA1ADORA2AADORA3ADORA2BIRAK1 | |
| SCHEMBL15425807 | 0.77 | ADORA1 (0.81) | ADORA1ADORA2AADORA3ADORA2BEGFR | |
| SCHEMBL22587438 | 0.76 | CYP1A2 (0.47) | ADORA1ADORA2AADORA3ADORA2BMAP4K4 | |
| SCHEMBL29426168 | 0.76 | CYP1A2 (0.47) | ADORA1ADORA2AADORA3ADORA2BMAP4K4 | |
| SCHEMBL4496406 | 0.76 | ADORA1 (0.78) | ADORA1ADORA2AADORA3ADORA2BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.